TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Alemtuzumab (Campath) to Treat T-Large Granular Lymphocyte Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
* INCLUSION CRITERIA:~Clinical history supportive of the diagnosis of T-LGL leukemia (i.e. a history of cytopenias with peripheral blood morphologic evidence of LGLs)~Immunophenotypic studies of peripheral blood showing an increased population of T-LGLs (suggested by staining with CD3+, CD8+ and CD16+ or CD57+) or gammadelta T cells~Restricted or clonal rearrangement of the T-cell receptor by PCR AND one or more of the following:~Severe neutropenia (less than 500 neutrophils/microliter); OR~Severe thrombocytopenia (less than 20,000 platelets/microliter), or moderate thrombocytopenia (less than 50,000 platelets/microliter) with active bleeding; OR~Symptomatic anemia with a hemoglobin less than 9 g/dL or red blood cell transfusion requirement of greater than 2 units/month for two months prior to initiation of Campath~Ages 18-85 (both inclusive)~EXCLUSION CRITERIA:~A reactive LGL lymphocytosis to a viral infection~Serologic evidence of HIV infection~Infection not adequately responding to appropriate therapy~Previous immunosuppressive therapy with alemtuzumab~History of carcinoma that is not considered cured (excluding non-melanoma skin carcinoma)~Moribund status or concurrent hepatic, renal, cardiac, neurologic, pulmonary, infectious, or metabolic disease of such severity that it would preclude the subject's ability to tolerate protocol therapy or that death within 7-10 days is likely~Current pregnancy or unwilling to take oral contraceptives or refrain from pregnancy if of childbearing potential~Not able to understand the investigational nature of the study or give informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Alemtuzumab in patients with T cell large granular lymphocytic leukemia (T-LGL) (Type: EXPERIMENTAL): Alemtuzumab (Campath) will be administered at 10 mg/dose IV for 10 days as an infusion over 2 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Dose Ranging Study Of PF-00868554 In Combination With PEGASYS And COPEGUS In Patients With Chronic Hepatitis C Genotype 1 Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Treatment naive (no prior treatment with IFN-a +/- RBV regimens.~* Subjects who have discontinued IFN-a containing regimens after \<2 weeks of therapy due to tolerability issues are considered treatment naive.~* HCV RNA \> 100,000 IU/mL at screening.~* Genotype 1.~* A diagnosis of chronic HCV infection for at least 6 months.~Exclusion Criteria:~* Evidence of acute or chronic infection with HIV or HBV.~* Exposure within the previous three months to an investigational anti-HCV agent.~* Evidence of severe or decompensated liver disease.~* Subjects with liver disease unrelated to HCV infection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): 500 mg BID
- B (Type: EXPERIMENTAL): 300 mg BID
- C (Type: EXPERIMENTAL): 200 mg BID
- D (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Blood glucose criteria must be met~* Previously responded, as defined by the protocol, to treatment with pioglitazone or rosiglitazone~* Body mass index (BMI) in the range 22-45~Exclusion Criteria:~* Type 1 diabetes~* Pregnancy or lactation~* Evidence of serious cardiovascular complications~* Evidence of serious diabetic complications~* Laboratory value abnormalities as defined by the protocol~* Known sensitivity to pioglitazone~* Other protocol-defined exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Vildagliptin 50 mg qd + pioglitazone 45 mg qd (Type: EXPERIMENTAL): Vildagliptin 50 mg qd + pioglitazone 45 mg qd for 24 weeks
- Vildagliptin 50 mg bid + pioglitazone 45 mg qd (Type: EXPERIMENTAL): Vildagliptin 50 mg bid + pioglitazone 45 mg qd for 24 weeks
- Vildagliptin placebo + pioglitazone 45 mg qd (Type: PLACEBO_COMPARATOR): Vildagliptin placebo + pioglitazone 45 mg qd for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Study of Dexamethasone Versus Laser Photocoagulation in Participants With Diabetic Macular Edema

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of diabetes mellitus (type 1 or type 2)~* Presence of macular edema~Exclusion Criteria:~* Anticipated need for ocular surgery in the study eye during the study~* Laser photocoagulation in the study eye within 3 months~* Cataract surgery within 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Laser Photocoagulation (Type: OTHER): Laser photocoagulation was administered in the study eye on Day 1, and on Months 3, 6, and 9, if retreatment indicated.
- Dexamethasone (Type: EXPERIMENTAL): Dexamethasone 700 μg was administered as intravitreal injection in the study eye on Day 1, Months 5, and 10.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of BETOPTIC S 0.25% and Timolol Gel-forming Solution 0.25% and 0.5% in Pediatric Patients With Glaucoma or Ocular Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
INCLUSION:~* Children 5 years old and younger~* require treatment for glaucoma or ocular hypertension~* whose vision is 20/80 or better~* have a cup-to-disc ratio of 0.8 or less~EXCLUSION:~* do not have abnormal fixation~* IOP greater than 36 mm Hg~* significant retinal disease~* penetrating keratoplasty~* severe ocular pathology~* optic atrophy~* eye surgery in the past 30 days~* cardiovascular abnormalities~* hypersensitivity to beta blockers

- Gender: MALE
- Minimum Age: 1 Week
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- Betaxolol (Type: EXPERIMENTAL): Two doses daily for 12 weeks
- TGFS 0.25% (Type: EXPERIMENTAL): Two doses daily for 12 weeks
- TGFS 0.5% (Type: EXPERIMENTAL): Two doses daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Investigating the Efficacy of a Dentifrice in Providing Long Term Relief From Dentinal Hypersensitivity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with self-reported history of dentinal hypersensitivity lasting more than 6 months but not more than 10 years.~* Participants with minimum of 20 natural teeth.~* At screening, a minimum of two accessible teeth (incisors, canines, premolars) that meet all of the following criteria.~  1. Teeth showing signs of facial/cervical gingival recession and/or signs of erosion or abrasion.~ 2. Teeth with Gingival Index score ≤1 and a clinical mobility of ≤1.~ 3. Teeth that are determined to be sensitive by the subject following a 1 second air blast to the cervical margin.~Exclusion Criteria:~* Presence of chronic debilitating disease which, in the opinion of the investigator, could affect study outcomes.~* Any condition which, in the opinion of the investigator, causes dry mouth.~* Tooth with evidence of current or recent caries, or reported treatment of decay in 12 months of screening.~* Participant using of a desensitising dentifrice within 6 weeks of screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- 0.454% stannous fluoride dentifrice (Type: EXPERIMENTAL): Participants to brush whole mouth with 1-inch strip of the test dentifrice (0.454% SnF) for one timed minute, followed by rinsing with 5 milliliter (mL) of water.
- 0.76% sodium monofluorophosphate dentifrice (Type: ACTIVE_COMPARATOR): Participants to brush whole mouth with 1-inch strip of the control dentifrice (0.76% NaMFP) for one timed minute, followed by rinsing with 5 mL of water.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of the Addition of Canagliflozin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must have a diagnosis of type 2 diabetes mellitus~* Must have a screening HbA1c of \>=7.5% to \<=10.5%~* Must be on metformin \>=1500 mg/day and sitagliptin 100 mg/day (or equivalent fixed dose combination) at a stable dose for at least 12 weeks before screening~Exclusion Criteria:~* History of diabetic ketoacidosis or T1DM, hereditary glucose-galactose malabsorption or primary renal glycosuria~* A myocardial infarction, unstable angina, revascularization procedure or cerebrovascular accident within 12 weeks before screening~* eGFR \<60 ml/min/1.73m2, or serum creatinine \>=1.4 mg/dL for men and \>=1.3 mg/dL for women~* Known significant liver disease (eg, acute hepatitis, chronic active hepatitis, cirrhosis)~* Major surgery (ie, requiring general anesthesia) within 12 weeks before screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Canagliflozin (JNJ-28431754) (Type: EXPERIMENTAL): Each participant will receive canagliflozin (JNJ-28431754) 100 mg once daily during the first 6 weeks, then the dose may be increased to 300 mg once daily.
- Placebo (Type: PLACEBO_COMPARATOR): Each participant will receive placebo (inactive medication) once daily for 28 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Acute Effect of Aclidinium on Hyperinflation and Ventilation Inhomogeneity in Severe COPD Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signature of informed consent~* COPD patients with age raging from 50 to 85 years old~* Patients with at least a history of COPD of one year~* COPD patients clinically stable in the last three months~* COPD subjects with Forced Expiratory Volume at one second (FEV1)\<50% of predicted value~* COPD subjects with Residual Volume (RV) \>125% predicted value~* FEV1/Forced Vital Capacity (FVC) \<88% (males) or \<89% (females) of Low Levels of Normality (LLN)~* COPD former or active smokers with at least a smoking history of 20 pack year~Exclusion Criteria:~* Acute Bronchial Exacerbation at recruitment~* Fertile women with age between 18 and 50 years old or with active period~* Pregnancy~* Subjects enrolled in other clinical trials or that have taken part in one of them in the month preceding the enrollment.~* FEV1/FVC more than 70% of predicted value in basal conditions~* FEV1 more than 70% of predicted value in basal conditions~* Known deficit of alpha 1 antitrypsin~* Subjects that underwent a Lung Volume Reduction Surgery (LVRS)~* Subjects with known positivity to Human Immunodeficiency Virus (HIV)~* Misuse of alcool or drugs~* Lack of compliance in performing respiratory tests~* Subjects not capable to follow the study prescriptions because of psychic disorders or language problems.~* Long Term Oxygen Therapy with flows \> 6 litres per minute (l/min) at rest

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Aclidinium - Glycopyrronium (Type: EXPERIMENTAL): Patients will assume Aclidinium Bromide 322 dry powder by Genuair inhaler and Glycopyrronium 44 dry powder inhaler by Breezehaler inhaler (placebo) after 72 hours from inhalatory therapy washout (only short acting bronchodilators permitted). Then, after 72 hours of inhalatory drugs washout (only short acting bronchodilators permitted), they will receive Glycopyrronium Bromide 322 mcg via Breezehaler inhaler and Aclidinium Bromide 322 dry powder by Genuair inhaler (placebo).
- Glycopyrronium - Aclidinium (Type: EXPERIMENTAL): Patients will assume Glycopyrronium Bromide 44 mcg dry powder by Breezehaler inhaler and Aclidinium Bromide 322 dry powder by Genuair inhaler (placebo) after 72 hours of inhalatory therapy washout (only short acting bronchodilators permitted). Then, after 72 hours of inhalatory drugs washout (only short acting bronchodilators permitted) they will receive Aclidinium Bromide 322 mcg via Genuair inhaler and Glycopyrronium Bromide 44 mcg dry powder by Breezehaler inhaler (placebo).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Topical Sm29 in Combination With Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- Clinical diagnosis of cutaneous leishmaniasis (typical ulcerated lesion); 1 to 2 ulcers; ulcer size ranging from 10-40mm; disease duration between 20-90 days.~Exclusion Criteria:~* Diabetes; Cardiovascular or kidney disease; HIV seropositivity; use of immunosupressive drugs; pregnancy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Topical Sm29 and Sbv (Type: EXPERIMENTAL): Use of topical Sm29 twice a day during 20 days and systemic Sbv during 20 days
- Topical Placebo and Sbv (Type: PLACEBO_COMPARATOR): Use of topical placebo twice a day during 20 days and systemic Sbv during 20 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Effectiveness and Safety Study of Decitabine in Patients With Myelodysplastic Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must have diagnosed with Myelodysplastic Syndrome (MDS) denovo (previously not present) or secondary as per the classification of French-American-British (FAB) and International Prognostic Scoring System (IPSS) greater than or eaul to 0.5 as determined by complete blood count (CBC), bone marrow assessment and bone marrow cytogenetics~* Must have an Eastern Oncology Cooperative Group (ECOG) performance status of 0-2~* Must have adequate hepatic and renal function as measured by the aspartate transaminase (AST), alanine transaminase (ALT), total bilirubin and serum creatinine, respectively~* Must have recovered from all toxic effects of prior therapy and not received any chemotherapy for a minimum of 4 weeks (6 weeks if the patient has been treated with a nitrosoureas) prior to the first dose of study drug - Woman must be postmenopausal, or surgically sterile, or abstinent, or, if sexually active, be practicing an effective method of birth control (eg, oral contraceptives, contraceptive injections, intrauterine device, double-barrier method, contraceptive patch, male partner sterilization)~Exclusion Criteria:~* Must not have a diagnosis of acute myeloid leukemia (greater than 30% bone marrow blasts) - Must not have received radiotherapy within 14 days before the first dose of study drug - Must not have any other prior cancer, other than superficial bladder cancer, basal cell skin and cervical cancer - Must not have associated autoimmune hemolytic anemia or immune thrombocytopenia and inaspirable bone marrow - Must not have a mental illness or any other condition (eg, uncontrolled cardiac or pulmonary disease, diabetes), that could prevent full cooperation with the study requirements.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 3-Day Dose schedule (Type: EXPERIMENTAL): Decitabine will be administered at a dose of 15 mg/m2 as a continuous intravenous infusion within a 3 hour period, repeated every 8 hours for 3 consecutive days. Cycles will be repeated every 6 weeks.
- 5-Day Dose schedule (Type: EXPERIMENTAL): Decitabine will be administered at a dose of 20 mg/m2 as a intravenous infusion within 1 hour, once daily for 5 consecutive days. Cycles will be repeated every 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Of Safety And Efficacy Of Ertugliflozin (PF-04971729, MK-8835) In Participants With Type 2 Diabetes (MK-8835-016)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Participants with type 2 diabetes on stable doses of background medicines for management of the diabetes; aged 18-70 years; body mass index between 23-45 kg/m\^2~Exclusion Criteria:~* Participants with type 1 diabetes, heart attack or stroke in last 6-months, uncontrolled blood pressure, significant kidney disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Placebo for ertugliflozin (1 mg or 5 mg and 25 mg) and placebo to sitagliptin, oral, once daily for 84 days
- Ertugliflozin 1 mg (Type: EXPERIMENTAL): Ertugliflozin 1 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days
- Ertugliflozin 5 mg (Type: EXPERIMENTAL): Ertugliflozin 5 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), and placebo to sitagliptin, oral, once daily for 84 days
- Ertugliflozin 10 mg (Type: EXPERIMENTAL): Ertugliflozin 10 mg, placebo for ertugliflozin (25 mg), and placebo to sitagliptin, oral, once daily for 84 days
- Ertugliflozin 25 mg (Type: EXPERIMENTAL): Ertugliflozin 25 mg, placebo for ertugliflozin (1 mg or 5 mg), and placebo to sitagliptin, oral, once daily for 84 days
- Sitagliptin 100 mg (Type: ACTIVE_COMPARATOR): Sitagliptin 100 mg, placebo for ertugliflozin (1 mg or 5 mg and 25 mg), oral, once daily for 84 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Lamotrigine on Neuropathic Facial Pain Using fMRI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18-60 years of age~* Right-handed non-smokers~* Diagnosed with facial pain~* Continuous pain for more than 3 months~* Spontaneous pain greater than 3 of 10~* Allodynia to brush greater than 5 of 10~Exclusion Criteria:~* Medications~* Depression~* Significant medical problems~* Claustrophobia~* Abnormal EKG~* Significant drug or alcohol history~* Positive drug screen~* Weight greater than 285 lbs~* History of allergy to anticonvulsants~* Tattoos with metallic ink on upper body~* Any neurostimulator devices, or metal cochlear, ocular, or cardiac implants or other metal near vital areas~* Exposure to shrapnel or metal filings~* Other metallic surgical hardware

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Lamotrigine to Placebo Crossover (Type: ACTIVE_COMPARATOR): The drug lamotrigine will be given for 9 weeks prior to imaging session 1. A rescue drug, Gabapentin, will be provided for pain control. Patients will taper off the Gabapentin 2 weeks before each scan date. After a taper and washout, placebo (cross over) will be administered. At the end of the trial (after imaging session 2), a taper for placebo will be given. Patients will be required to maintain a pain diary during the study, documenting the perceived effects of the drug on the severity of their pain and keeping track of their subjective pain ratings day to day. Patients will also complete the McGill Pain Questionnaire at each visit.
- Placebo to Lamotrigine Crossover (Type: ACTIVE_COMPARATOR): The placebo will be given for 9 weeks prior to imaging session 1. A rescue drug, Gabapentin, will be provided for pain control. Patients will taper off the Gabapentin 2 weeks before each scan date. After a taper and washout, the drug lamotrigine (cross over) will be administered. At the end of the trial (after imaging session 2), a taper for drug will be given. Patients will be required to maintain a pain diary during the study, documenting the perceived effects of the drug on the severity of their pain and keeping track of their subjective pain ratings day to day. Patients will also complete the McGill Pain Questionnaire at each visit.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete